Incannex secures US patent for IHL-42X sleep apnoea therapy to 2040

Incannex Healthcare has received a US patent from the United States Patent and Trademark Office (USPTO) covering the composition and therapeutic methods of IHL-42X, the company's oral combination therapy candidate for obstructive sleep apnoea (OSA). The patent carries a baseline expiry date of 9 July 2040, and Incannex said it is exploring eligibility for patent term extension following any future FDA approval, which could lengthen the exclusivity window further.

The grant arrives at a meaningful moment in the programme's development. IHL-42X already holds FDA Fast Track designation and has generated positive topline data from the RePOSA Phase 2 study. The company is now moving toward the DReAMzz dose optimisation study, a crossover design intended to refine the dosing profile ahead of a planned Phase 3 programme. Incannex said central IRB approval has been received, the first site has cleared all regulatory hurdles and is preparing to screen patients, and clinical drug supply has been shipped to a distribution partner for secondary packaging and labelling.

Pipeline context

Joel Latham, President and Chief Executive Officer of Incannex, described the patent as "another major milestone in the evolution of the IHL-42X program," adding that OSA "affects an estimated one billion people globally and remains a significantly underserved market where current treatment options continue to suffer from poor long-term patient adherence." The company argues this creates a commercial opening for a safe, well-tolerated oral therapy that avoids the compliance problems associated with continuous positive airway pressure (CPAP), currently the standard of care for moderate-to-severe OSA.

Incannex did not disclose the specific active ingredients in IHL-42X beyond describing it as a combination therapy, nor did the announcement include the Phase 2 efficacy or safety data underpinning the Fast Track designation. The DReAMzz study is expected to generate data on objective sleep metrics and patient-reported outcomes, two endpoints that regulators and payers have increasingly emphasised as the OSA field moves toward pharmacological options.

Market and competitive landscape

The pharmaceutical OSA space has attracted sustained interest from developers seeking alternatives to CPAP and mandibular advancement devices, both of which carry high long-term non-adherence rates. Several companies are pursuing oral pharmacotherapy approaches targeting different mechanisms, including agents acting on upper airway muscle tone and on the arousal threshold. Regulatory precedent in the space is still forming: the FDA approved the first hypoglossal nerve stimulator as a device-based option several years ago, but a dedicated oral pharmaceutical approval for OSA in adults remains elusive in the US market, which gives any well-characterised Phase 3 asset a degree of first-mover value if the clinical data support approval.

For Incannex, a NASDAQ-listed clinical-stage company based in Melbourne and New York, the patent strengthens the asset's out-licensing and partnership appeal. Intellectual property coverage through 2040 at minimum provides a commercial partner with sufficient runway to justify the investment required to advance through Phase 3 and a potential New Drug Application. The company's pipeline also includes IHL-675A for rheumatoid arthritis and PSX-001 for generalised anxiety disorder, though IHL-42X is positioned as the lead asset.

Investors will be watching for the first DReAMzz patient enrolment announcement and, subsequently, any data readout that clarifies the dose-response relationship before Incannex commits to a Phase 3 protocol. The company noted that DEA Schedule I researcher registrations are still in process at some sites, which may affect the pace of enrolment given the regulatory steps involved.